The UK’s Office of Fair Trading announced the referral of the completed buyout of eye correction company Ultralase by competitor Optimax to the Competition Commission in what reports say suggests the OFT may have found cause of concern regarding the deal. The deal occurred in November of last year without informing the OFT; it was not until the companies’ merger was undeway that the regulator started probing the buyout. Reports say by the initiation of the review, several Ultralase clinics were already replaced by Optimax clinics. In its review, the OFT found six geographical areas whose competition was threatened by the deal. Reports say the Commission will reach a decision on the deal by January 12 of next year.
Featured News
Italian Ski-Pass Operators Agree to €30 Million Payout After Antitrust Probe
Aug 8, 2026 by
CPI
Delaware Court Orders Verisk to Pursue $2.35 Billion AccuLynx Deal Despite FTC Review
Aug 8, 2026 by
CPI
Trump Pushes Back on AI Rules as Congress Weighs Tighter Controls
Aug 8, 2026 by
CPI
Warren Raises Antitrust Concerns Over Private Home Listings
Aug 8, 2026 by
CPI
PlayStation Antitrust Cases Put Closed Console Stores Under Scrutiny
Aug 8, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes